DVI-001 is a cyclic peptide program with high-affinity cyclic peptide candidates engineered for the treatment of Inflammatory Bowel Disease (IBD). Developed using Divamics’ AI-enabled multi-scale simulation platform, this asset overcomes traditional limitations in peptide stability and oral bioavailability. Having successfully completed early-stage optimization, DVI-001 exhibits a superior developability profile and robust efficacy signals as it approaches Preclinical Candidate (PCC) selection. We are actively seeking strategic partners for licensing or collaborative development to accelerate this high-potential program into the clinic.

DVI-002 is a bispecific antibody program representing a frontier approach to IBD therapy. By using our AI-driven structural modeling and developability assessment, we have optimized the asset for maximum binding synergy and minimal immunogenicity. DVI-002 is currently in the lead optimization phase and is available for co-development or strategic partnership opportunities.

DVI-003 is a small-molecule program targeting the global health challenges of diabetes and obesity. By utilizing AI-driven molecular design, we have identified novel scaffolds that demonstrate exceptional metabolic stability and target selectivity. The asset has shown favorable pharmacokinetic properties in early-stage optimization, positioning it as a highly competitive candidate in the metabolic space. Divamics is open to discussing licensing, co-development, or regional rights for this rapidly advancing program.